An improved method for the measurement of lidocaine and its metabolites in rat plasma.

An improved method is described for the quantitation of lidocaine and its dominant metabolites in rat plasma, 3-hydroxy-lidocaine glucuronide and 3-hydroxy-MEG-X glucuronide. Frozen plasma samples (100-200 microliters) were thawed and deproteinated by precipitation with acetonitrile, before the conversion of glucuronidates into their respective hydroxylated forms by acid hydrolysis. After extraction with solid-phase C18 cartridge chromatography, the metabolites and parent drug were analyzed by capillary gas chromatography-nitrogen phosphorus detection, without derivativization. A detection limit of 0.005 microgram/ml for lidocaine and nonglucuronidated metabolites and 0.01 microgram/ml for glucuronidated metabolites was achieved. The method offers significant improvements in sensitivity relative to existing techniques, which should be of specific benefit to studies in which sample volume is limited, such as those concerned with the pharmacokinetics of lidocaine metabolism in small-animal pain state models.

[1]  T. Yaksh,et al.  Simultaneous extraction of sufentanil and midazolam from human plasma. , 1996, Clinica chimica acta; international journal of clinical chemistry.

[2]  G. Strichartz.  Protracted relief of experimental neuropathic pain by systemic local anesthetics. How, where, and when. , 1995, Anesthesiology.

[3]  S L Shafer,et al.  Prolonged Alleviation of Tactile Allodynia by Intravenous Lidocaine in Neuropathic Rats , 1995, Anesthesiology.

[4]  B. Bruguerolle,et al.  Rapid Simultaneous Determination of Lidocaine, Bupivacaine, and Their Two Main Metabolites Using Capillary Gas‐Liquid Chromatography with Nitrogen Phosphorus Detector , 1994, Therapeutic drug monitoring.

[5]  A. Scholer,et al.  Assessment of lidocaine metabolite formation in comparison with other quantitative liver function tests. , 1993, Journal of hepatology.

[6]  C. Starmer,et al.  Kinetics of interaction of the lidocaine metabolite glycylxylidide with the cardiac sodium channel. Additive blockade with lidocaine. , 1992, Circulation research.

[7]  A. Camm,et al.  Relative efficacy and safety of intravenous drugs for termination of sustained ventricular tachycardia , 1990, The Lancet.

[8]  R. Kawai,et al.  A new lidocaine metabolite, omega-diethylamino-2-hydroxymethyl-6-methylacetanilide. , 1986, Drug metabolism and disposition: the biological fate of chemicals.

[9]  R. Kawai,et al.  Simultaneous quantitation of lidocaine and its four metabolites by high-performance liquid chromatography: application to studies on in vitro and in vivo metabolism of lidocaine in rats. , 1985, Journal of pharmaceutical sciences.

[10]  R. Boyes,et al.  The tissue distribution, metabolism and excretion of lidocaine in rats, guinea pigs, dogs and man. , 1972, The Journal of pharmacology and experimental therapeutics.

[11]  E. Smith,et al.  The acute antiarrhythmic and toxic effects in mice and dogs of 2-ethylamino-2',6-'acetoxylidine (L-86), a metabolite of lidocaine. , 1971, The Journal of pharmacology and experimental therapeutics.